☆ 4.6 Letter

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

HAEMATOLOGICA (2018)

Get Full Text
Add to Collection

Journal

HAEMATOLOGICA
Volume 103, Issue 10, Pages E473-E479

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2018.189969

Keywords

-

Categories

Hematology

Funding

  1. Deutsche Krebshilfe [1095969, 111424]
  2. Deutsche Forschungsgemeinschaft (DFG) [Ju 295/13-1]
  3. Janssen Pharmaceuticals
  4. MSD Pharma

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.